Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUE NYSEAMERICAN:MAIA NASDAQ:OTLK NYSEAMERICAN:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$21.90-3.3%$177.45$4.97▼$41.42$88.60M2.371.22 million shs58,145 shsMAIAMAIA Biotechnology$1.39+7.8%$1.33$0.87▼$3.19$84.51M0.21490,023 shs1.12 million shsOTLKOncobiologics$0.73-1.4%$0.28$0.16▼$3.39$88.23M0.3231.33 million shs31.42 million shsVNRXVolitionRX$2.67-7.3%$3.08$1.91▼$18.80$22.24M1.03293,711 shs156,613 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma0.00%+2.00%+48.58%-91.31%-96.14%MAIAMAIA Biotechnology0.00%+8.59%+4.51%-38.50%-22.35%OTLKOncobiologics0.00%+135.56%+192.00%+73.52%-55.21%VNRXVolitionRX0.00%-14.70%+1.91%-37.32%-72.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$21.90-3.3%$177.45$4.97▼$41.42$88.60M2.371.22 million shs58,145 shsMAIAMAIA Biotechnology$1.39+7.8%$1.33$0.87▼$3.19$84.51M0.21490,023 shs1.12 million shsOTLKOncobiologics$0.73-1.4%$0.28$0.16▼$3.39$88.23M0.3231.33 million shs31.42 million shsVNRXVolitionRX$2.67-7.3%$3.08$1.91▼$18.80$22.24M1.03293,711 shs156,613 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma0.00%+2.00%+48.58%-91.31%-96.14%MAIAMAIA Biotechnology0.00%+8.59%+4.51%-38.50%-22.35%OTLKOncobiologics0.00%+135.56%+192.00%+73.52%-55.21%VNRXVolitionRX0.00%-14.70%+1.91%-37.32%-72.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 1.00SellN/AN/AMAIAMAIA Biotechnology 0.00N/AN/AN/AOTLKOncobiologics 2.00Hold$4.50516.44% UpsideVNRXVolitionRX 2.60Moderate Buy$46.671,647.82% UpsideCurrent Analyst Ratings BreakdownLatest VNRX, CUE, OTLK, and MAIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026OTLKOncobiologics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/20/2026VNRXVolitionRX CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold4/20/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2026VNRXVolitionRX HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $20.003/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/18/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/11/2026OTLKOncobiologics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 5/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$27.47M3.23N/AN/A$5.34 per share4.10MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.46 per shareN/AOTLKOncobiologics$1.35M65.35N/AN/A($0.24) per share-3.04VNRXVolitionRX$1.73M12.86N/AN/A($4.00) per share-0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$26.60M-$5.58N/AN/AN/A-59.65%-98.30%-53.69%8/18/2026 (Estimated)MAIAMAIA Biotechnology-$22.40M-$1.38N/AN/AN/AN/A-284.80%-142.94%8/10/2026 (Estimated)OTLKOncobiologics-$62.42M-$1.17N/AN/AN/AN/AN/A-291.28%8/13/2026 (Estimated)VNRXVolitionRX-$23.36M-$0.56N/AN/AN/A-997.49%N/A-289.87%8/13/2026 (Estimated)Latest VNRX, CUE, OTLK, and MAIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026OTLKOncobiologics-$0.12-$0.16-$0.04-$0.05$4.39 million$0.13 million5/14/2026Q1 2026CUECue Biopharma-$3.30-$1.08+$2.22-$1.08$2.50 million$5.69 million5/14/2026Q1 2026VNRXVolitionRX-$0.70-$0.97-$0.27-$0.97$1.52 million$0.99 million5/11/2026Q1 2026MAIAMAIA Biotechnology-$0.18-$0.14+$0.04-$0.14N/AN/A3/23/2026Q4 2025MAIAMAIA Biotechnology-$0.13-$0.08+$0.05-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/AVNRXVolitionRXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A3.573.57MAIAMAIA BiotechnologyN/A5.595.59OTLKOncobiologicsN/A0.540.45VNRXVolitionRXN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%MAIAMAIA Biotechnology5.65%OTLKOncobiologics11.20%VNRXVolitionRX8.09%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma14.56%MAIAMAIA Biotechnology19.81%OTLKOncobiologics2.80%VNRXVolitionRX8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma604.05 million3.46 millionOptionableMAIAMAIA Biotechnology960.80 million48.76 millionNot OptionableOTLKOncobiologics20120.86 million117.48 millionOptionableVNRXVolitionRX808.33 million7.61 millionNot OptionableVNRX, CUE, OTLK, and MAIA HeadlinesRecent News About These CompaniesVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsMay 27, 2026 | prnewswire.comVolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | finance.yahoo.comVolitionRX (NYSEAMERICAN:VNRX) Stock Passes Below 50-Day Moving Average - Should You Sell?May 23, 2026 | americanbankingnews.comVolitionRX Earnings Call Balances Breakthroughs and RisksMay 20, 2026 | tipranks.comVolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...May 15, 2026 | finance.yahoo.comVolitionRX Earnings Call: Breakthrough Science, Cash Burn RiskMay 15, 2026 | tipranks.comVolitionRx Limited (VNRX) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comVolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | prnewswire.comVolitionRx (VNRX) price target increased by 1,618.09% to 29.79May 14, 2026 | msn.comVolitionRX Ltd.May 12, 2026 | marketwatch.comVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateMay 11, 2026 | prnewswire.comVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsMay 6, 2026 | prnewswire.comVolitionRx Enacts One-for-Twenty Reverse Stock SplitApril 29, 2026 | theglobeandmail.comVolition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingApril 29, 2026 | prnewswire.comVolitionRx (VNRX) price target decreased by 17.48% to 1.73April 28, 2026 | msn.comVNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1 ...April 28, 2026 | finance.yahoo.comVolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanApril 23, 2026 | prnewswire.comD Boral Capital downgrades VolitionRx (VNRX)April 21, 2026 | msn.comVolition Launches rNuQ™ Webshop Broadening Product RangeApril 20, 2026 | prnewswire.comVolitionRx Earnings Call: Breakthroughs Amid Funding StrainApril 4, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNRX, CUE, OTLK, and MAIA Company DescriptionsCue Biopharma NASDAQ:CUE$21.90 -0.74 (-3.27%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$21.87 -0.03 (-0.14%) As of 05/29/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.MAIA Biotechnology NYSEAMERICAN:MAIA$1.39 +0.10 (+7.75%) Closing price 05/29/2026 04:10 PM EasternExtended Trading$1.37 -0.02 (-1.44%) As of 05/29/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Oncobiologics NASDAQ:OTLK$0.73 -0.01 (-1.35%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.37%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.VolitionRX NYSEAMERICAN:VNRX$2.67 -0.21 (-7.29%) Closing price 05/29/2026 04:10 PM EasternExtended Trading$2.72 +0.05 (+1.91%) As of 05/29/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
